NASDAQ:KPTI Karyopharm Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.14 +0.41 (+8.67%) (As of 07/5/2022 01:45 PM ET) Add Compare Share Today's Range$4.59▼$5.1650-Day Range$4.15▼$6.7452-Week Range$4.02▼$14.73Volume84,921 shsAverage Volume2.62 million shsMarket Capitalization$408.22 millionP/E RatioN/ADividend YieldN/APrice Target$11.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Karyopharm Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside131.4% Upside$11.57 Price TargetShort InterestBearish28.77% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.93Based on 2 Articles This WeekInsider TradingSelling Shares$2.15 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.06) to ($1.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.34 out of 5 starsMedical Sector174th out of 1,428 stocksPharmaceutical Preparations Industry73rd out of 680 stocks 3.2 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.57, Karyopharm Therapeutics has a forecasted upside of 131.4% from its current price of $5.00.Amount of Analyst CoverageKaryopharm Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted28.77% of the float of Karyopharm Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 2.7 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search Interest10 people have searched for KPTI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,153,045.00 in company stock.Percentage Held by Insiders10.24% of the stock of Karyopharm Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.75% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($2.06) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Karyopharm Therapeutics (NASDAQ:KPTI) StockKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More KPTI Stock News HeadlinesJune 22, 2022 | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Fifty Day Moving Average of $6.05June 15, 2022 | finance.yahoo.comKaryopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase AgreementJune 15, 2022 | seekingalpha.comBiogen terminates 2018 asset purchase agreement with Karyopharm TherapeuticsJune 13, 2022 | seekingalpha.comKaryopharm director sells ~$3.4M in company sharesJune 12, 2022 | americanbankingnews.comDeepika Pakianathan Sells 325,977 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) StockJune 12, 2022 | americanbankingnews.comBrokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $11.57June 1, 2022 | finance.yahoo.comKaryopharm to Participate at the Jefferies Healthcare ConferenceMay 27, 2022 | msn.comLooking Into Karyopharm Therapeutics's Return On Capital EmployedMay 26, 2022 | finance.yahoo.comKaryopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual MeetingMay 26, 2022 | seekingalpha.comKaryopharm wins FDA’s Orphan Drug status for leading asset in myelofibrosisMay 25, 2022 | seekingalpha.comKaryopharm begins dosing in late-stage study of selinexor combo therapy for multiple myelomaMay 20, 2022 | seekingalpha.comEU drug regulator panel recommends expanding indication for Karyopharm's NexpovioMay 20, 2022 | finance.yahoo.comKaryopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple MyelomaMay 12, 2022 | finance.yahoo.comKaryopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid CongressMay 6, 2022 | finance.yahoo.comIs Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Popular Amongst Institutions?May 6, 2022 | seekingalpha.comKaryopharm Therapeutics, Inc. (KPTI) CEO Richard Paulson on Q1 2022 Results - Earnings Call TranscriptMay 6, 2022 | finance.yahoo.comKaryopharm Therapeutics (KPTI) Q1 2022 Earnings Call TranscriptMay 5, 2022 | markets.businessinsider.comAnalyst Ratings for Karyopharm TherapeuticsMay 5, 2022 | finance.yahoo.comKaryopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2022 | investing.comKaryopharm Therapeutics Tops Q1 EPS by 10cMay 5, 2022 | finance.yahoo.comKaryopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company ProgressMay 4, 2022 | benzinga.comKaryopharm Therapeutics Earnings PreviewApril 28, 2022 | finance.yahoo.comKaryopharm to Report First Quarter 2022 Financial Results on May 5, 2022April 25, 2022 | nasdaq.comKaryopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 20, 2022 | nasdaq.comPre-market Movers: NFLX, RMNI, LYRA, BW, NEWP…See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees442Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/05/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$11.57 High Stock Price Forecast$22.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+125.1%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,090,000.00 Net Margins-46.14% Pretax Margin-46.03% Return on EquityN/A Return on Assets-37.92% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.11 Sales & Book Value Annual Sales$209.82 million Price / Sales1.95 Cash FlowN/A Price / Cash FlowN/A Book Value($1.05) per share Price / Book-4.90Miscellaneous Outstanding Shares79,420,000Free Float71,286,000Market Cap$408.22 million OptionableOptionable Beta0.05 Karyopharm Therapeutics Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Karyopharm Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares. View analyst ratings for Karyopharm Therapeutics or view top-rated stocks. What is Karyopharm Therapeutics' stock price forecast for 2022? 6 Wall Street analysts have issued 1-year price objectives for Karyopharm Therapeutics' shares. Their KPTI stock forecasts range from $6.00 to $22.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $11.57 in the next twelve months. This suggests a possible upside of 129.1% from the stock's current price. View analysts' price targets for Karyopharm Therapeutics or view top-rated stocks among Wall Street analysts. How has Karyopharm Therapeutics' stock performed in 2022? Karyopharm Therapeutics' stock was trading at $6.43 at the beginning of 2022. Since then, KPTI stock has decreased by 21.5% and is now trading at $5.05. View the best growth stocks for 2022 here. When is Karyopharm Therapeutics' next earnings date? Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Karyopharm Therapeutics. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its quarterly earnings results on Thursday, May, 5th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.10. The company had revenue of $47.67 million for the quarter, compared to analysts' expectations of $34.78 million. During the same quarter in the prior year, the business posted ($0.77) earnings per share. View Karyopharm Therapeutics' earnings history. Who are Karyopharm Therapeutics' key executives? Karyopharm Therapeutics' management team includes the following people: Mr. Richard A. Paulson M.B.A., Pres, CEO & Director (Age 55, Pay $1.27M)Dr. Sharon Shacham M.B.A., Ph.D., Co-Founder & Chairman of Scientific Advisory Board (Age 52, Pay $766.54k)Mr. Michael P. Mason CPA, M.B.A., Exec. VP, CFO & Treasurer (Age 47, Pay $692.39k) (LinkedIn Profile)Mr. Ran Frenkel R.Ph., RPh, Exec. VP & Chief Devel. Officer (Age 53, Pay $667.87k)Dr. Mansoor Raza Mirza M.D., Clinical Consultant, Member of Scientific Advisory Board & Independent Director (Age 61, Pay $146.14k)Mr. Cameron Peters, VP of Fin., Assistant Treasurer & Principal Accounting Officer (Age 62)Mr. Pierre S. Sayad M.S., Ph.D., VP of Global Medical & Scientific AffairsMs. Elhan Webb C.F.A., Sr. VP of Investor RelationsMr. Michael J. Mano J.D., Sr. VP, Gen. Counsel & Sec. (Age 45)Ms. Lisa Meletta J.D., VP of Legal & Chief Compliance Officer What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees. Who are some of Karyopharm Therapeutics' key competitors? Some companies that are related to Karyopharm Therapeutics include Travere Therapeutics (TVTX), Ligand Pharmaceuticals (LGND), Supernus Pharmaceuticals (SUPN), Axsome Therapeutics (AXSM), BridgeBio Pharma (BBIO), Lyell Immunopharma (LYEL), BELLUS Health (BLUSF), Zentalis Pharmaceuticals (ZNTL), Taro Pharmaceutical Industries (TARO), Day One Biopharmaceuticals (DAWN), Prothena (PRTA), Sierra Oncology (SRRA), Agios Pharmaceuticals (AGIO), Madrigal Pharmaceuticals (MDGL) and Amylyx Pharmaceuticals (AMLX). View all of KPTI's competitors. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). What is Karyopharm Therapeutics' stock symbol? Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI." How do I buy shares of Karyopharm Therapeutics? Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karyopharm Therapeutics' stock price today? One share of KPTI stock can currently be purchased for approximately $5.05. How much money does Karyopharm Therapeutics make? Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $401.07 million and generates $209.82 million in revenue each year. The company earns $-124,090,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. How many employees does Karyopharm Therapeutics have? Karyopharm Therapeutics employs 442 workers across the globe. How can I contact Karyopharm Therapeutics? Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for Karyopharm Therapeutics is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com. This page (NASDAQ:KPTI) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
